A new device category for the largest unserved group in heart failure.
Ceryx is backed by institutional investors and is now preparing its next funding round. We also work with cardiac rhythm management companies on development and commercial partnerships.
Why Ceryx
A large population with no device option
Most patients with heart failure with reduced ejection fraction have a narrow QRS and are not eligible for CRT. They are managed on drugs alone and remain the biggest driver of heart failure hospitalisation.
A familiar procedure and care pathway
Cysoni is a single-lead atrial pacemaker. Implanting cardiologists, hospitals and payers already understand the procedure, the follow-up and the reimbursement codes it resembles.
Clinical data in hand, implant under way
The RSA-Pace randomised study is complete, the first implantable device has been built, and the implantable pulse generator is in development with ISO 13485 partners.
Protected and differentiated
Eight patent families cover the therapy, the circuits and the sensing. The approach does not depend on any incumbent’s platform and can be licensed or integrated.
$15M raised to date
Figures as announced publicly.
Led by the Development Bank of Wales and Parkwalk Advisors, with BGF, taking total funding to $15M. Supports completion of RSA-Pace and development of the implantable Cysoni system.
Development Bank of Wales, Icehouse Ventures, Parkwalk Advisors, BGF and a consortium of angel investors. Funded the move from preclinical work into the first clinical study.
Spun out of the Universities of Bath and Bristol. Supported by Innovate UK’s ICURe programme, SETsquared and early angel and institutional investment.
Next funding round
We are speaking with specialist medtech and cardiovascular investors about the round that will take Cysoni through its first implant study. Qualified investors can request the investor deck and data room access.
Request investor materialsDevelopment and commercial partnerships
Ceryx’s therapy can be delivered as a standalone device or integrated into an existing pacing platform. We welcome conversations with cardiac rhythm management companies about co-development, licensing and distribution.
Start a partnering conversation